Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medro vs This Gen Wellness

Medro
Graded #252

Higher grade

vs+6.700000000000003
This Gen Wellness
Graded #405

Lower grade

The verdict

Medro takes it — 63.6/100 to 56.9/100.

Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedro +5
50
45
Dose & formulationMedro +37
77
40
Clinical oversightThis Gen Wellness +16
71
87
Labs & monitoringEven
52
52
FulfillmentMedro +18
92
74
Contract termsThis Gen Wellness +12
33
45
Medro · left barThis Gen Wellness · right bar

The numbers

MetricMedroThis Gen Wellness
WeighScore63.6/10056.9/100
GradeCC
Scorecard rank#252#405
Semaglutide$199/mo (compounded)Not disclosed
Tirzepatide$299/mo (compounded)Not disclosed
CoverageAll 50 states1 state
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Medro

Graded #252 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
This Gen Wellness

Graded #405 · C

Strengths

  • Requires a synchronous live audio-video visit with a New York-licensed clinician — prescriptions are never issued from the intake form alone
  • Assessment and clinician review are free; you only pay if treatment is prescribed and you choose to proceed
  • Names its legal entity (ThisGen, LLC) and specifies New York governing law in its terms
  • No long-term contracts — plans can be paused or stopped
  • The same clinician follows your care, with ongoing secure messaging between visits

Where it loses points

  • Publishes no prices at all — 'We don't list flat prices on the website'; cost is disclosed only after a clinician reviews your assessment
  • Serves New York only — 'we currently operate exclusively for patients located in New York'
  • Dispensing pharmacies are not named, only described as 'licensed U.S. pharmacies'
  • Does not state whether its semaglutide and tirzepatide are compounded or brand-name
  • Does not bill insurance; verifying any reimbursement is the patient's responsibility

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard